Abstract 166P
Background
Gallbladder (GB) cancer shows high prevalence in South Korea, and tends to show high fatality. In surgically fit patients, radical resection aiming an R0 margin combined with lymphadenectomy is the mainstay of curative-intent therapy. In spite of R0 resection, however, high recurrence rate is observed in GB cancer, demanding a need to figure out risk factors related to recurrence after surgery.
Methods
This is a single center, retrospective cohort study conducted on 148 patients with GB cancer who underwent R0 resection between January 1st, 2014 and December 31st, 2019. Several variables were analyzed with statistical tools to identify risk factors related to prognosis. Early recurrence, defined as progression of disease within one year after R0 resection, was studied with logistic regression analysis.
Results
Early recurrence was observed in 15.5% (N=23) of patients. Based on statistical analysis, independent risk factors of early recurrence were age over 65 (hazard ratio [HR] 4.44, 95% confidence interval [CI] 1.25 - 15.75, p=0.021), glycated hemoglobin (HbA1c) level more than 6.5% (HR 5.00, 95% CI 1.37 – 18.31, p=0.015), surgical T stage more than T3 (HR 16.76, 95% CI 5.76 – 48.73, p<0.001), surgical N stage more than N1 (HR 5.82, 95% CI 2.22 – 15.28, p<0.001), pathologic differentiation of moderate to poor differentiation (HR 5.20, 95% CI 1.64 – 16.48, p=0.005), reversed albumin-globulin ratio (HR 0.08, 95% CI 0.01 – 0.45, p=0.004), high c-reactive protein (CRP) level (HR 1.22, 95% CI 1.08 – 1.38, p=0.001), and high carbohydrate antigen (CA) 19-9 level (HR 3.53, 95% CI 1.36 – 9.13, p=0.009). Table: 166P
Variable | Univariate analysis | ||
OR | 95% CI | P | |
Age (≥ 65 vs < 65) | 4.44 | (1.25 - 15.75) | .021 |
Sex (male vs female) | 0.86 | (0.34 - 2.17) | .743 |
Smoking (yes vs no) | 1.02 | (0.27 - 3.83) | .974 |
Alcohol (yes or no) | 0.76 | (0.24 - 2.44) | .649 |
HbA1C (≥ 6.5 vs < 6.5) | 5.00 | (1.37 - 18.31) | .015 |
Surgical T stage (T3 + T4 vs T1 + T2) | 16.76 | (5.76 - 48.73) | <.001 |
Surgical N stage (N1 + N2 vs N0) | 5.82 | (2.22 - 15.28) | <.001 |
Pathology differentiation (non-well vs well) | 5.20 | (1.64 - 16.48) | .005 |
WBC | 0.99 | (0.89 - 1.10) | .875 |
AST | 1.00 | (1.00 - 1.00) | .728 |
ALT | 1.00 | (1.00 - 1.01) | .653 |
Bilirubin | 1.05 | (0.90 - 1.23) | .549 |
Albumin-globulin ratio (≥ 1.0 vs < 1.0) | 0.08 | (0.01 - 0.45) | .004 |
CRP | 1.22 | (1.08 - 1.38) | .001 |
CA19-9 (≥ 39.0 vs < 39.0) | 3.53 | (1.36 - 9.13) | .009 |
Conclusions
Advanced pathologic stage and high inflammatory marker levels, reflecting high tumor burden, were related with poor surgical outcome. Interestingly, high HbA1c level was connected with early recurrence as well. In conclusion, active screening for early detection, reducing inflammatory conditions, and managing diabetes might reduce early recurrence after R0 resection of GB cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Pusan National University Hospital.
Funding
This work was supported by clinical research grant from Pusan National University in 2023.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
73TiP - Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
78P - First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
79P - Accelerated identification of recurrent neoantigens for the development of off-the-shelf cancer vaccines
Presenter: Le Son Tran
Session: Poster Display
Resources:
Abstract
80P - Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
Presenter: Yanmin Wu
Session: Poster Display
Resources:
Abstract
81P - A first-in-human, multiple dose and dose escalation phase I study to investigate the safety, tolerability and antitumor activity of SmarT cells plus PD-1 blocking antibodies in patients with far advanced/metastatic solid tumors
Presenter: Qin Liu
Session: Poster Display
Resources:
Abstract
82P - NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Presenter: Gloria Chan
Session: Poster Display
Resources:
Abstract
83P - The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors
Presenter: Yinan Shen
Session: Poster Display
Resources:
Abstract
84P - T cell receptor repertoire profiles of tumor -infiltrating lymphocytes improves neoantigen prioritization for personalized cancer immunotherapy
Presenter: Tran Nguyen
Session: Poster Display
Resources:
Abstract
85P - Oligometastatic solid tumors: Disease characteristics and role of local therapies
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
86P - Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study
Presenter: Changxing Li
Session: Poster Display
Resources:
Abstract